Evolution of diverse classes of renin inhibitors through the years

Aspartic Acid Proteases as Therapeutic Targets

Volumn 45, Issue , 2011, Pages 297-324

  Tice, Colin M ^a   Singh, Suresh B ^a  

^a Vitae Pharmaceuticals   (United States)

Author keywords

Angiotensin; Ciprokiren; Enalkiren; Plasma renin activity; Remikiren; X ray crystallography; Zankiren aliskiren

Indexed keywords

EID: 85017365772     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527630943.ch11     Document Type: Chapter

References (132)

1. Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T.B., Flegal, K., Ford, E., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S., Ho, M., Howard, V., Kissela, B., Kittner, S., Lackland, D., Lisabeth, L., Marelli, A., McDermott, M., Meigs, J., Mozaffarian, D., Nichol, G., Odonnell, C., Roger, V., Rosamond, W., Sacco, R., Sorlie, P., Stafford, R., Steinberger, J., Thom, T., Wasserthiel-Smoller, S., Wong, N., Wylie-Rosett, J., and Hong, Y. (2009) Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 119, e21-e181.
2. Tyndall, J.D.A., Nall, T., and Fairlie, D.P. (2005) Proteases universally recognize beta strands in their active sites. Chemical Reviews, 105, 973-999.
3. Murzin, A.G., Brenner, S.E., Hubbard, T., and Chothia, C. (1995) SCOP: a structural classification of proteins database for the investigation of sequences and structures. Journal of Molecular Biology, 247, 536-541.
4. Zaman, M.A., Oparil, S., and Calhoun, D.A. (2002) Drugs targeting the renin-angiotensin-aldosterone system. Nature Reviews. Drug Discovery, 1, 621-636.
5. Fisher, N.D.L. and Hollenberg, N.K. (2005) Renin inhibition: what are the therapeutic opportunities? Journal of the American Society of Nephrology, 16, 592-601.
6. Stanton, A. (2003) Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. American Journal of Cardiovascular Drugs, 3, 389-394.
7. Samani, N.J., Cumin, F., Kelly, M., and Wood, J.M. (1994) Expression of components of the RAS during prolonged blockade at different levels in primates. The American Journal of Physiology, 267, E612-E619.
8. Eder, J., Hommel, U., Cumin, F., Martoglio, B., and Gerhartz, B. (2007) Aspartic proteases in drug discovery. Current Pharmaceutical Design, 13, 271-285.
9. Tewksbury, D.A., Dart, R.A., and Travis, J. (1981) The amino terminal amino acid sequence of human angiotensinogen. Biochemical and Biophysical Research Communications, 99, 1311-1320.
10. Morgan, L., Pipkin, F.B., and Kalsheker, N. (1996) Angiotensinogen: molecular biology, biochemistry and physiology. The International Journal of Biochemistry & Cell Biology, 28, 1211-1222.
11. Suguna, K., Padlan, E.A., Smith, C.W., Carlson, W.D., and Davies, D.R. (1987) Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. Proceedings of the National Academy of Sciences of the United States of America, 84, 7009-7011.
12. Davies, D.R. (1990) The structure and function of the aspartic proteinases. Annual Review of Biophysics and Biophysical Chemistry, 19, 189-215.
13. Sali, A., Veerapandian, B., Cooper, J.B., Foundling, S.I., Hoover, D.J., and Blundell, T.L. (1989) High-resolution X-ray diffraction study of the complex between endothiapepsin and an oligopeptide inhibitor: the analysis of the inhibitor binding and description of the rigid body shift in the enzyme. The EMBO Journal, 8, 2179-2180.
14. Hyland, L.J., Tomaszek, T.A., Jr., and Meek, T.D. (1991) Human immunodeficiency virus-1 protease. 2. Use ofpH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry, 30, 8454-8461.
15. Gomez, J. and Freire, E. (1995) Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin. Journal of Molecular Biology, 252, 337-340.
16. Wang, Y.-X., Freedberg, D.I., Yamazaki, T., Wingfield, P.T., Stahl, S.J., Kaufman, J.D., Kiso, Y., and Torchia, D.A. (1996) Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry, 35, 9945-9950.
17. Silva, A.M., Cachau, R.E., Sham, H.L., and Erickson, J.W. (1996) Inhibition and catalytic mechanism of HIV-1 aspartic protease. Journal of Molecular Biology, 255, 321-330.
18. Smith, R., Brereton, I.M., Chai, R.Y., and Kent, S.B.H. (1996) Ionization states of the catalytic residues in HIV-1 protease. Nature Structural Biology, 3, 946-950.
19. Xie, D.,Gulnik, S., Collins, L.,Gustchina, E., Suvorov, L., and Erickson, J.W. (1997) Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues. Biochemistry, 36, 16166-16172.
20. Northrop, D.B. (2001) Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Accounts of Chemical Research, 34, 790-797.
21. Rajamani, R. and Reynolds, C.H. (2004) Modeling the protonation states of the catalytic aspartates in beta-secretase. Journal of Medicinal Chemistry, 47, 5159-5166.
22. Park, H. and Lee, S. (2003) Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. Journal of the American Chemical Society, 125, 16416-16422.
23. Cascella, M., Micheletti, C., Rothlisberger, U., and Carloni, P. (2005) Evolutionarily conserved functional mechanics across pepsin-like and retroviral aspartic proteases. Journal of the American Chemical Society, 127, 3734-3742.
24. Gorfe, A.A. and Caflisch, A. (2005) Functional plasticity in the substrate binding site of beta-secretase. Structure (London, England: 1993), 13, 1487-1498.
25. Sielecki, A.R., Hayakawa, K., Fujinaga, M., Murphy, M.E.P., Fraser, M., Muir, A.K., Carilli, C.T., Lewicki, J.A., Baxter, J.D., and James, M.N.G. (1989) Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. Science, 243, 1346-1350.
26. Dhanaraj, V., Dealwis, C.G., Frazao, C., Badasso, M., Sibanda, B.L., Tickle, I.J., Cooper, J.B., Driessen, H.P.C., Newman, M., Aguilar, C.,Wood, S.P., Blundell,T.L., Hobart, P.M., Geoghegan, K.F., Ammirati, M.J., Danley, D.E., Oconnor, B.A., and Hoover, D.J. (1992) X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature, 357, 466-470.
27. Veerapandian, B., Cooper, J.B., Sali, A., Blundell,T.L., Rosati, R.L., Dominy, B.W., Damon, D.B., and Hoover, D.J. (1992) Direct observation by X-ray analysis of the tetrahedral 'intermediate' of aspartic proteinases. Protein Science: A Publication of the Protein Society, 1, 322-330.
28. Coates, L., Tuan, H.-F., Tomanicek, S., Kovalevsky, A., Mustyakimov, M., Erskine, P., and Cooper, J. (2008) The catalytic mechanism of an aspartic proteinase explored with neutron and X-ray diffraction. Journal of the American Chemical Society, 130, 7235-7237.
29. Pilote, L., McKercher, G., Thibeault, D., and Lamarre, D. (1995) Enzymic characterization of purified recombinant human renin. Biochemistry and Cell Biology, 73, 163-170.
30. Nasir, U.M., Suzuki, F., Nagai, T., Nakagawa, T., and Nakamura, Y. (1999) Tyrosine-83 of human renin contributes to biphasic pH dependence of the renin-angiotensinogen reaction. Bioscience, Biotechnology, and Biochemistry, 63, 1143-1150.
31. Nasir, U.M., Takahashi, K., Nagai, T., Nakagawa, T., Suzuki, F., and Nakamura, Y. (1998) Two peaks in pH dependence of renin-angiotensinogen reaction. Bioscience, Biotechnology, and Biochemistry, 62, 338-340.
32. Gruninger-Leitch, F., Schlatter, D., Kung, E., Nelbock, P., and Dobeli, H. (2002) Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. The Journal of Biological Chemistry, 277, 4687-4693.
33. Collins, J.F. and Fine, R. (1981) The enzymic digestion of elastin at acidic pH. Biochimica et Biophysica Acta, 657, 295-303.
34. Rahuel, J., Priestle, J., and Gruetter, M.G. (1991) The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor. Journal of Structural Biology, 107, 227-230.
35. Rahuel, J., Rasetti, V., Maibaum, J., Rueger, H., Goschke, R., Cohen, N.C., Stutz, S., Cumin, F., Fuhrer, W., Wood, J.M., and Grutter, M.G. (2000) Structurebased drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chemistry & Biology, 7, 493-504.
36. Cody, W.L., Holsworth, D.D., Powell, N.A., Jalaie, M., Zhang, E., Wang, W., Samas, B., Bryant, J., Ostroski, R., Ryan, M.J., and Edmunds, J.J. (2005) The discovery and preparation of disubstituted novel amino-arylpiperidine-based renin inhibitors. Bioorganic & Medicinal Chemistry, 13, 59-68.
37. Vieira, E., Binggeli, A., Breu, V., Bur, D., Fischli, W., Guller, R., Hirth, G., Marki, H.P.,Muller, M., Oefner, C., Scalone, M., Stadler, H., Wilhelm, M., and Wostl, W. (1999) Substituted piperidines: highly potent renin inhibitors due to induced fit adaptation of the active site. Bioorganic & Medicinal Chemistry Letters, 9, 1397-1402.
38. Guller, R., Binggeli, A., Breu, V., Bur, D., Fischli, W., Hirth, G., Jenny, C., Kansy, M., Montavon, F.,Muller, M., Oefner, C., Stadler, H., Vieira, E., Wilhelm, M., Wostl, W., and Marki, H.P. (1999) Piperidine-renin inhibitors compounds with improved physicochemical properties. Bioorganic & Medicinal Chemistry Letters, 9, 1403-1408.
39. Oefner, C., Binggeli, A., Breu, V., Bur, D., Clozel, J.P., Darcy, A., Dorn, A., Fischli, W., Gruninger, F., Guller, R., Hirth, G., Marki, H.P., Mathews, S., Muller, M., Ridley, R.G., Stadler, H., Vieira, E., Wilhelm, M., Winkler, F.K., and Wostl, W. (1999) Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? Chemistry & Biology, 6, 127-131.
40. Marki, H.P., Binggeli, A., Bittner, B., Bohner-Lang, V., Breu, V., Bur, D., Coassolo, P., Clozel, J.P., Darcy, A., Doebeli, H., Fischli, W., Funk, C., Foricher, J., Giller, T., Gruninger, F., Guenzi, A., Guller, R., Hartung, T., Hirth, G., Jenny, C., Kansy, M., Klinkhammer, U., Lave, T., Lohri, B., Luft, F.C., Mervaala, E.M., Muller, D.N., Muller, M., Montavon, F., Oefner, C., Qiu, C., Reichel, A., Sanwald-Ducray, P., Scalone, M., Schleimer, M., Schmid, R., Stadler, H., Treiber, A., Valdenaire, O., Vieira, E.,Waldmeier, P.,Wiegand-Chou, R., Wilhelm, M.,Wostl, W., Zell, M., and Zell, R. (2001) Piperidine renin inhibitors: from leads to drug candidates. Farmaco (Societa Chimica Italiana: 1989), 56, 21-27.
41. Holsworth, D.D., Cai, C., Cheng, X.-M., Cody, W.L., Downing, D.M., Erasga, N., Lee, C., Powell, N.A., Edmunds, J.J., Stier, M., Jalaie, M., Zhang, E., McConnell, P., Ryan, M.J., Bryant, J., Li, T., Kasani, A., Hall, E., Subedi, R., Rahim, M., and Maiti, S. (2006) Ketopiperazine-based renin inhibitors: optimization of the 'C' ring. Bioorganic & Medicinal Chemistry Letters, 16, 2500-2504.
42. Powell, N.A., Clay, E.H., Holsworth, D.D., Bryant, J.W., Ryan, M.J., Jalaie, M., Zhang, E., and Edmunds, J.J. (2005) Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors. Bioorganic & Medicinal Chemistry Letters, 15, 2371-2374.
43. Bukhtiyarov, Y., Zecher, M., Panemangalore, R., Wu, Z., Bruno, J.G., Yuan, J., Xu, Z., Dillard, L.W., McGeehan, G.M., Harrison, R.K., and Scott, B.B. (2007) Cloning, characterization and site-directed mutagenesis of canine renin. Journal of Biochemistry, 142, 671-680.
44. Boger, J., Lohr, N.S., Ulm, E.H., Poe, M., Blaine, E.H., Fanelli, G.M., Lin, T.Y., Payne, L.S., Schorn, T.W., LaMont, B.I., Vassil, T.C., Stabilito, I.I., and Veber, D.F. (1983) Novel renin inhibitors containing the amino acid statine. Nature, 303, 81-91.
45. Ganten, D., Wagner, J., Zeh, K., Bader, M., Michel, J.B., Paul, M., Zimmermann, F., Ruf, P., Hilgenfeldt, U., and Ganten, U. (1992) Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proceedings of the National Academy of Sciences of the United States of America, 89, 7806-7811.
46. Bohlender, J., Fukamizu, A., Lippoldt, A., Nomura, T., Dietz, R., Menard, J., Murakami, K., Luft, F.C., and Ganten, D. (1997) High human renin hypertension in transgenic rats. Hypertension, 29, 428-434.
47. Bohlender, J., Menard, J., Wagner, J., Luft, F.C., and Ganten, D. (1996)Human renin-dependent hypertension in rats transgenic for human angiotensinogen. Hypertension, 27, 535-541.
48. Fukamizu, A., Sugimura, K., Takimoto, E., Sugiyama, F., Seo, S.M., Takahashi, S., Hatae, T., Kawijara, N., Yagami, K., and Murakami, K. (1993) Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. The Journal of Biological Chemistry, 268, 11617.
49. Luft, F.C., Mervaala, E., Muller, D.N., Gross, V., Schmidt, F., Park, J.K., Schmitz, C., Lippoldt, A., Breu, V., Dechend, R., Dragun, D., Schneider, W., Ganten, D., and Haller, H. (1999) Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension, 33, 212-218.
50. Kokubu, T., Ueda, E., Fujimoto, S., Hiwada, K., and Kato, A. (1968) Peptide inhibitors of the renin-angiotensin system. Nature, 217, 456-460.
51. Burton, J., Cody, R.J., Jr., Herd, J.A., and Haber, E. (1980) Specific inhibition of renin by an angiotensinogen analog: studies in sodium depletion and renindependent hypertension. Proceedings of the National Academy of Sciences of the United States of America, 77, 5476-5481.
52. Papaioannou, S., Hansen, D., Jr., Babler, M., Yang, P.C., Bittner, S., Miller, A., and Clare, M. (1985) New class of inhibitors specific for human renin. Clinical and Experimental Hypertension. Part A, Theory and Practice, A7, 1243-1250.
53. Cody, R.J., Burton, J., Evin, G., Poulsen, K., Herd, J.A., and Haber, E. (1980) A substrate analog inhibitor of renin that is effective in vivo. Biochemical and Biophysical Research Communications, 97, 230-240.
54. Wolfenden, R. (1972) Analog approaches to the structure of the transition state in enzyme reactions. Accounts of Chemical Research, 5, 10-18.
55. Greenlee, W.J. (1990) Renin inhibitors. Medicinal Research Reviews, 10, 173-180.
56. Rosenberg, S.H. (1995) Renin Inhibitors, Elsevier Science, vol. 32, pp. 37-114.
57. Umezawa, H., Aoyagi, T., Morishima, H., Matsuzaki, M., Hamada, M., and Takeuchi, T. (1970) Pepstatin, a new pepsin inhibitor produced by actinomycetes. The Journal of Antibiotics, 23, 259-260.
58. Thaisrivongs, S., Pals, D.T.,Harris, D.W., Kati, W.M., and Turner, S.R. (1986) Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo. Journal of Medicinal Chemistry, 29, 2088-2090.
59. Mangiapane, M.L., Wester, R.T., Holt, W.F., Ellery, S.S., Simpson, K.A., Schelhorn, T.M., Smith, A.H., Purcell, I.M., and Murphy, W.R. (1995) Terlakiren: an orally active renin inhibitor in the guinea pig. Drug Development Research, 34, 361-368.
60. Hanson, G.J., Baran, J.S., Lindberg, T., Walsh, G.M., Papaioannou, S.E., Babler, M., Bittner, S.E., Yang, P.C., and Dal Corobbo, M. (1985) Dipeptide glycols: a new class of renin inhibitors. Biochemical and Biophysical Research Communications, 132, 155-160.
61. Kleinert, H.D., Luly, J.R., Marcotte, P.A., Perun, T.J., Plattner, J.J., and Stein, H. (1988) Renin inhibitors. Improvements in the stability and biological activity of small peptides containing novel Leu-Val replacements. FEBS Letters, 230, 38-42.
62. Buehlmayer, P., Caselli, A., Fuhrer, W., Goeschke, R., Rasetti, V., Rueger, H., Stanton, J.L., Criscione, L., and Wood, J.M. (1988) Synthesis and biological activity of some transition-state inhibitors of human renin. Journal of Medicinal Chemistry, 31, 1839-1846.
63. Wood, J.M., Criscione, L., De Gasparo, M., Buhlmayer, P., Rueger, H., Stanton, J.L., Jupp, R.A., and Kay, J. (1989) CGP 38 560: orally active, low-molecular-weight renin inhibitor with high potency and specificity. Journal of Cardiovascular Pharmacology, 14, 221-226.
64. Boger, J., Payne, L.S., Perlow, D.S., Lohr, N.S., Poe, M., Blaine, E.H., Ulm, E.H., Schorn, T.W., LaMont, B.I., Lin, T.-Y., Kawai, M., Rich, D.H., and Veber, D.F. (1985) Renin inhibitors. Syntheses of subnanomolar, competitive, transitionstate analog inhibitors containing a novel analog of statine. Journal of Medicinal Chemistry, 28, 1779-1790.
65. Cumin, F., Schnell, C., Richert, P., Raschdorf, F., Probst, A., Schmid, K., Wood, J.M., and De Gasparo, M. (1990) Pharmacokinetics and tissue distribution of the renin inhibitor N-(2-(R)-benzyl-3-tert-butyl-sulfonyl-propionyl)-His-Cha(c)Val-N-butylamine in marmosets. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 18, 831-835.
66. De Gasparo, M., Cumin, F., Nussberger, J., Guyenne, T.T., Wood, J.M., and Menard, J. (1989) Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. British Journal of Clinical Pharmacology, 27, 587-596.
67. Clozel, J.P. and Fischli, W. (1993) Discovery of remikiren as the first orally active renin inhibitor. Arzneimittel-Forschung, 43, 260-270.
68. Fischli, W., Clozel, J.P., El Amrani, K., Wostl, W., Neidhart, W., Stadler, H., and Branca, Q. (1991) Ro 42-5892 is a potent orally active renin inhibitor in primates. Hypertension, 18, 22-31.
69. Clozel, J.P. and Fischli, W. (1993) Comparative effects of three different potent renin inhibitors in primates. Hypertension, 22, 9-17.
70. Coassolo, P., Fischli,W., Clozel, J.P., and Chou, R.C. (1996) Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates. Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 26, 333-340.
71. Jauch, R., Schmid, P., Fischli, W., Meister, W., Maurer, R., and Wendt, G. (1996) Excretion and metabolism of remikiren, a potent orally active inhibitor of primate renin. Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 26, 285-290.
72. Richter, W.F., Whitby, B.R., and Chou, R.C. (1996) Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals. Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 26, 243-250.
73. Kleinbloesem, C.H., Weber, C., Fahrner, E., Dellenbach, M., Welker, H., Schroter, V., and Belz, G.G. (1993) Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clinical Pharmacology and Therapeutics, 53, 585-591.
74. Camenzind, E., Nussberger, J., Juillerat, L., Munafo, A., Fischli, W., Coassolo, P., Van Brummelen, P., Kelinbloesem, C.H., Waeber, B., and Brunner, H.R. (1991) Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans. Journal of Cardiovascular Pharmacology, 18, 299-307.
75. Kiowski,W., Linder, L., Kleinbloesem, C., van Brummelen, P., and Buhler, F.R. (1992) Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation, 85, 1-8.
76. Azizi, M., Guyene, T.T., Chatellier, G., and Menard, J. (1994) Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension. Journal of Hypertension, 12, 419-420.
77. van den Meiracker, A.H., Admiraal, P.J., Derkx, F.H., Kleinbloesem, C., Man int Veld, A.J., van Brummelen, P., Mulder, P., and Schalekamp, M.A. (1993) Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. Journal of Hypertension, 11, 831-841.
78. Rongen, G.A., Lenders, J.W., Kleinbloesem, C.H., Weber, C., Welker, H., Fahrner, E., Pozenel, H., Woittiez, A.J., Haug, G., and Buchmann, M.S. (1993) Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension. Clinical Pharmacology and Therapeutics, 54, 567-571.
79. Fischli, W., Clozel, J.P., Breu, V., Buchmann, S., Mathews, S., Stadler, H., Vieira, E., and Wostl, W. (1994) Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. Hypertension, 24, 163-170.
80. Kleinert, H.D., Martin, D., Chekal, M.A., Kadam, J., Luly, J.R., Plattner, J.J., Perun, T.J., and Luther, R.R. (1988) Effects of the renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity. Hypertension, 11, 613-621.
81. Delabays, A., Nussberger, J., Porchet, M., Waeber, B., Hoyos, P., Boger, R., Glassman, H., Kleinert, H.D., Luther, R., and Brunner, H.R. (1989)Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension, 13, 941-951.
82. Cordero, P., Fisher, N.D., Moore, T.J., Gleason, R., Williams, G.H., and Hollenberg, N.K. (1991) Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans. Hypertension, 17, 510-511.
83. Boger, R.S., Glassman, H.N.,Cavanaugh, J.H., Schmitz, P.J., Lamm, J., Moyse, D., Cohen, A., Kleinert, H.D., and Luther, R.R. (1990) Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension. Hypertension, 15, 835-841.
84. Weber, M.A., Neutel, J.M., Essinger, I., Glassman, H.N., Boger, R.S., and Luther, R. (1990) Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation, 81, 1768-1770.
85. Bursztyn, M., Gavras, I., Tifft, C.P., Luther, R., Boger, R., and Gavras, H. (1990) Effects of a novel renin inhibitor in patients with essential hypertension. Journal of Cardiovascular Pharmacology, 15, 493-500.
86. Glassman, H.N., Kleinert, H.D., Boger, R.S., Moyse, D.M., Griffiths, A.N., and Luther, R.R. (1990) Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor. Journal of Cardiovascular Pharmacology, 16. (Suppl. 4), S76-S81.
87. Boyd, S.A., Fung, A.K., Baker, W.R., Mantei, R.A., Armiger, Y.L., Stein, H.H., Cohen, J., Egan, D.A., Barlow, J.L., and Klinghofer, V. (1992) C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties. Journal ofMedicinal Chemistry, 35, 1735-1740.
88. Kleinert, H.D., Rosenberg, S.H., Baker, W.R., Stein, H.H., Klinghofer, V., Barlow, J., Spina, K., Polakowski, J., Kovar, P., Cohen, J., and Denissen, J. (1992) Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science, 257, 1940-1950.
89. Rosenberg, S.H., Spina, K.P., Woods, K.W., Polakowski, J., Martin, D.L., Yao, Z., Stein, H.H., Cohen, J., Barlow, J.L., Egan, D.A., Tricarico, K.A., Baker, W.R., and Kleinert, H.D. (1993) Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides. Journal of Medicinal Chemistry, 36, 449-450.
90. Rosenberg, S.H., Spina, K.P., Condon, S.L., Polakowski, J., Yao, Z., Kovar, P., Stein, H.H., Cohen, J., Barlow, J.L., Klinghofer, V., Egan, D.A., Tricarico, K.A., Perun, T.J., Baker, W.R., and Kleinert, H.D. (1993) Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3-[[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-lalanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517). Journal of Medicinal Chemistry, 36, 460-467.
91. Menard, J., Boger, R.S., Moyse, D.M., Guyene, T.T., Glassman, H.N., and Kleinert, H.D. (1995) Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation, 91, 330-340.
92. Patt,W.C.,Hamilton, H.W., Taylor, M.D., Ryan, M.J., Taylor, D.G., Jr., Connolly, C.J.C., Doherty, A.M., Klutchko, S.R., Sircar, I., Steinbaugh, B.A., Batley, B.L., Painchaud, C.A., Rapundalo, S.T., Michniewicz, B.M., and Olson, S.C. (1992) Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. Journal of Medicinal Chemistry, 35, 2562-2570.
93. Patt, W.C., Hamilton, H.W., Ryan, M.J., Painchaud, C.A., Taylor, M.D., Rapundalo, S.T., Batley, B.L., Connolly, C.J.C., and Taylor, D.G., Jr. (1992) A novel orally active renin inhibitor containing 2-amino-4-thiazolyl-alanine at P2 with a long duration of action in a primate model of hypertension. Medicinal Chemistry Research, 2, 10-15.
94. Stewart, B.H., Lu, R.H.H., and Chan, O.H. (1992) Absorption, biotransformation and excretion of the renin inhibitor, CI-992, and its P1-P10 isostere in the bile-duct-cannulated (BDC) rat. Pharmaceutical Research, 9, S295.
95. Hamilton, H.W., Steinbaugh, B.A., Stewart, B.H., Chan, O.H., Schmid, H.L., Schroeder, R., Ryan, M.J., Keiser, J., Taylor, M.D., Blankley, C.J., Kaltenbronn, J.S., Wright, J., and Hicks, J. (1995) Evaluation of physicochemical parameters important to the oral bioavailability of peptide-like compounds: implications for the synthesis of renin inhibitors. Journal of Medicinal Chemistry, 38, 1446-1455.
96. Bradbury, R.H. and Rivett, J.E. (1991) 1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 3. Synthesis and biological properties of aminodeoxystatine and difluorostatone derivatives. Journal of Medicinal Chemistry, 34, 151-157.
97. Simoneau, B., Lavallee, P., Anderson, P.C., Bailey, M., Bantle, G., Berthiaume, S., Chabot, C., Fazal, G., Halmos, T., Ogilvie, W.W., Poupart, M.-A., Thavonekham, B., Xin, Z., Thibeault, D., Bolger, G., Panzenbeck, M., Winquist, R., and Jung, G.L. (1999) Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy. Bioorganic & Medicinal Chemistry, 7, 489-508.
98. Poss, M.A., Reid, J.A., Free, C.A., Rogers, W.L.,Weber, H., Ryono, D.E., Dejneka,T., DeForrest, J.M., Waldron, T.L., Brittain, R.J., Weller, H.N., Cimarusti, M.P., and Petrillo, E.W. (1993) Diol sulfonamides: a potent and novel class of inhibitors of human renin. Bioorganic & Medicinal Chemistry Letters, 3, 2739-2740.
99. Rosenberg, S.H., Woods, K.W., Kleinert, H.D., Stein, H., Nellans, H.N., Hoffman, D.J., Spanton, S.G., Pyter, R.A., Cohen, J., Egan, D.A., Plattner, J.J., and Perun, T.J. (1989) Azido glycols: potent, low molecular weight renin inhibitors containing an unusual post scissile site residue. Journal of Medicinal Chemistry, 32, 1371-1378.
100. Plummer, M.S., Shahripour, A., Kaltenbronn, J.S., Lunney, E.A., Steinbaugh, B.A., Hamby, J.M., Hamilton, H.W., Sawyer, T.K., Humblet, C., Doherty, A.M., Taylor, M.D., Hingorani, G., Batley, B.L., and Rapundalo, S.T. (1995) Design and synthesis of renin inhibitors: incorporation of transition-state isostere side chains that span from the S1 to the S3 binding pockets and examination of P3-modified renin inhibitors. Journal of Medicinal Chemistry, 38, 2893-2905.
101. Hanessian, S. and Raghavan, S. (1994) Design and synthesis of a prototypical non-peptidic inhibitor model for the enzyme renin. Bioorganic & Medicinal Chemistry Letters, 4, 1697-1700.
102. Rasetti, V., Cohen, N.C., Rueeger, H., Goeschke, R., Maibaum, J., Cumin, F., Fuhere, W., and Wood, J.M. (1996) Bioactive hydroxyethylene dipeptide isosteres with hydrophobic (P3-P1)-moieties. A novel strategy towards small non-peptide renin inhibitors. Bioorganic & Medicinal Chemistry Letters, 6, 1589-1594.
103. Lefker, B.A., Hada, W.A., Wright, A.S., Martin, W.H., Stock, I.A., Schulte, G.K., Pandit, J., Danley, D.E., Ammirati, M.J., and Sneddon, S.F. (1995) Rational design, synthesis, and X-ray structure of renin inhibitors with extended P1 side-chains. Bioorganic & Medicinal Chemistry Letters, 5, 2623-2630.
104. Goschke, R., Cohen, N.C., Wood, J.M., and Maibaum, J. (1997) Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyloctanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin. Bioorganic & Medicinal Chemistry Letters, 7, 2735-2740.
105. Hanson, G.J., Clare, M., Summers, N.L., Lim, L.W., Neidhart, D.J., Shieh, H.S., and Stevens, A.M. (1994) Renin inhibitor SC-51106 complexed with human renin: discovery of a new binding site adjacent to P3. Bioorganic & Medicinal Chemistry, 2, 909-918.
106. Tice, C.M., Xu, Z., Yuan, J., Simpson, R.D., Cacatian, S.T., Flaherty, P.T., Zhao, W., Guo, J., Ishchenko, A., Singh, S.B., Wu, Z., Scott, B.B., Bukhtiyarov, Y., Berbaum, J., Mason, J., Panemangalore, R., Cappiello, M.G., Mueller, D., Harrison, R.K., McGeehan, G.M., Dillard, L.W., Baldwin, J.J., and Claremon, D.A. (2009) Design and optimization of renin inhibitors: orally bioavailable alkyl amines. Bioorganic & Medicinal Chemistry Letters, 19, 3541-3545.
107. Goschke, R., Stutz, S., Rasetti, V., Cohen, N.C., Rahuel, J., Rigollier, P., Baum, H.P., Forgiarini, P., Schnell, C.R., Wagner, T., Gruetter, M.G., Fuhrer, W., Schilling, W., Cumin, F., Wood, J.M., and Maibaum, J. (2007) Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyloctanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin. Journal of Medicinal Chemistry, 50, 4818-4831.
108. Maibaum, J., Stutz, S., Goschke, R., Rigollier, P., Yamaguchi, Y., Cumin, F., Rahuel, J., Baum, H.P., Cohen, N.C., Schnell, C.R., Fuhrer,W., Gruetter, M.G., Schilling, W., and Wood, J.M. (2007) Structural modification of the P20 position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyloctanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. Journal ofMedicinal Chemistry, 50, 4832-4844.
109. Wood, J.M., Schnell, C.R., Cumin, F., Menard, J., and Webb, R.L. (2005) Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. Journal of Hypertension, 23, 417-426.
110. Dechend, R., Shagdarsuren, E., Gratze, P., Fiebeler, A., Pilz, B., Meiners, S., Derer, W., Feldman, D.L., Webb, R., and Muller, D.N. (2007) Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. Journal of the renin-angiotensin-aldosterone system, 8, 81-84.
111. Pilz, B., Shagdarsuren, E., Wellner, M., Fiebeler, A., Dechend, R., Gratze, P., Meiners, S., Feldman, D.L., Webb, R.L., Garrelds, I.M., Danser, A.H.J., Luft, F.C., and Mueller, D.N. (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in doubletransgenic rats. Hypertension, 46, 569-576.
112. Kelly, D.J., Zhang, Y., Moe, G., Naik, G., and Gilbert, R.E. (2007) Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia, 50, 2398-2404.
113. Siragy, H.M., Kar, S., and Kirkpatrick, P. (2007) Aliskiren. Nature Reviews. Drug Discovery, 6, 779-780.
114. Jensen, C.,Herold, P., and Brunner, H.R. (2008) Aliskiren: the first renin inhibitor for clinical treatment. Nature Reviews. Drug Discovery, 7, 399-410.
115. Waldmeier, F., Glaenzel, U., Wirz, B., Oberer, L., Schmid, D., Seiberling, M., Valencia, J., Riviere, G.-J., End, P., and Vaidyanathan, S. (2007) Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35, 1418-1428.
116. Vaidyanathan, S., Jarugula, V., Dieterich Hans, A., Howard, D., and Dole William, P. (2008) Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clinical Pharmacokinetics, 47, 515-521.
117. Duprez, D.A. (2009) Aliskiren: the next innovation in renin-angiotensin-aldosterone system blockade. Aging Health, 5, 269-279.
118. Musini, V.M., Fortin, P.M., Bassett, K., and Wright, J.M. (2009) Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a cochrane systematic review. Journal of Human Hypertension, 23, 495-502.
119. Sever, P.S.,Gradman, A.H., and Azizi, M. (2009) Managing cardiovascular and renal risk: the potential of direct renin inhibition. Journal of the Renin-Angiotensin-Aldosterone System, 10, 65-76.
120. Yamaguchi, Y., Menear, K., Cohen, N.-C., Mah, R., Cumin, F., Schnell, C., Wood, J.M., and Maibaum, J. (2009) The P1 N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin. Bioorganic & Medicinal Chemistry Letters, 19, 4863-4867.
121. Bittner, B., Chou, R., Schleimer, M., Morgenroth, B., Zell, M., and Lave, T. (2002) Preformulation approaches to improve the oral bioavailability of two novel piperidine renin inhibitors in dog. Arzneimittel-Forschung, 52, 593-599.
122. Major, T.C., Olszewski, B., Rosebury, W., Okerberg, C., Carlson, T., Ostroski, R., Schroeder, R., Kowala, M.C., and Leadley, R. (2008) A nonpeptide. piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. Cardiovascular Drugs and Therapy, 22, 469-478.
123. Holsworth, D.D., Powell, N.A., Downing, D.M., Cai, C., Cody, W.L., Ryan, J.M., Ostroski, R., Jalaie, M., Bryant, J.W., and Edmunds, J.J. (2005) Discovery of novel non-peptidic ketopiperazine-based renin inhibitors. Bioorganic & Medicinal Chemistry, 13, 2657-2664.
124. Powell, N.A., Clay, E.H., Holsworth, D.D., Bryant, J.W., Ryan, M.J., Jalaie, M., and Edmunds, J.J. (2005) Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors. Bioorganic & Medicinal Chemistry Letters, 15, 4713-4716.
125. Bezencon, O., Bur, D.,Weller, T., Richard-Bildstein, S., Remen, L., Sifferlen, T., Corminboeuf, O., Grisostomi, C., Boss, C., Prade, L., Delahaye, S., Treiber, A., Strickner, P., Binkert, C., Hess, P., Steiner, B., and Fischli, W. (2009) Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. Journal ofMedicinal Chemistry, 52, 3689-3702.
126. Donofrio, A., Coppo, F., Squire, M., Burton, G., Semus, S., Hubbard, J., and Rivero, R. (2009) Discovery of trisubstituted triazines as potent renin inhibitors. Abstract of Papers presented at 238th ACS National Meeting, Washington, DC, August 16-20, 2009, p. MEDI-188.
127. Yokokawa, F. and Maibaum, J. (2008) Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000-2008. Expert Opinion on Therapeutic Patents, 18, 581-602.
128. Holsworth, D.D., Jalaie, M., Belliotti, T., Cai, C., Collard, W., Ferreira, S., Powell, N.A., Stier, M., Zhang, E., McConnell, P., Mochalkin, I., Ryan, M.J., Bryant, J., Li, T., Kasani, A., Subedi, R., Maiti, S.N., and Edmunds, J.J. (2007) Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors. Bioorganic & Medicinal Chemistry Letters, 17, 3575-3580.
129. Congreve, M., Aharony, D., Albert, J., Callaghan, O., Campbell, J., Carr, R.A.E., Chessari, G., Cowan, S., Edwards, P.D., Frederickson, M., McMenamin, R., Murray, C.W., Patel, S., and Wallis, N. (2007) Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of betasecretase. Journal of Medicinal Chemistry, 50, 1124-1132.
130. Powell, N.A., Ciske, F.L., Cai, C., Holsworth, D.D., Mennen, K., Van Huis, C.A., Jalaie, M., Day, J., Mastronardi, M., McConnell, P., Mochalkin, I., Zhang, E., Ryan, M.J., Bryant, J., Collard, W., Ferreira, S., Gu, C., Collins, R., and Edmunds, J.J. (2007) Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors. Bioorganic & Medicinal Chemistry, 15, 5912-5949.
131. Landon, M.R., Lancia, D.R., Jr., Yu, J., Thiel, S.C., and Vajda, S. (2007) Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. Journal of Medicinal Chemistry, 50, 1231-1240.
132. Rosenberg, S.H., and Boyd, S.A. (1997) Renin Inhibitors in Antihypertensive Drugs (eds P.A. Uan Zweiten and W.J. Greenlee) Harwood Academic Publishers, pp. 77-111.